125 related articles for article (PubMed ID: 12191583)
1. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine.
Murphy J; Flynn JJ; Cannon DM; Guiry PJ; McCormack P; Baird AW; McBean GJ; Keenan AK
Eur J Pharmacol; 2002 May; 444(1-2):61-7. PubMed ID: 12191583
[TBL] [Abstract][Full Text] [Related]
2. Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro.
Quinn ST; Guiry PJ; Schwab T; Keenan AK; McBean GJ
Auton Autacoid Pharmacol; 2006 Oct; 26(4):335-44. PubMed ID: 16968472
[TBL] [Abstract][Full Text] [Related]
3. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent.
Huang X; Marona-Lewicka D; Nichols DE
Eur J Pharmacol; 1992 Dec; 229(1):31-8. PubMed ID: 1473561
[TBL] [Abstract][Full Text] [Related]
4. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro.
Gobbi M; Moia M; Pirona L; Ceglia I; Reyes-Parada M; Scorza C; Mennini T
J Neurochem; 2002 Sep; 82(6):1435-43. PubMed ID: 12354291
[TBL] [Abstract][Full Text] [Related]
5. Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain.
Hashimoto K
Neurosci Lett; 1993 Apr; 152(1-2):17-20. PubMed ID: 7685864
[TBL] [Abstract][Full Text] [Related]
6. In vitro neuronal and vascular responses to 5-HT in rats chronically exposed to MDMA.
Cannon DM; Keenan AK; Guiry PJ; Buon C; Baird AW; McBean GJ
Br J Pharmacol; 2001 Dec; 134(7):1455-60. PubMed ID: 11724751
[TBL] [Abstract][Full Text] [Related]
7. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
Callaghan PD; Irvine RJ; Daws LC
Neurochem Int; 2005 Oct; 47(5):350-61. PubMed ID: 15979209
[TBL] [Abstract][Full Text] [Related]
8. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
Hekmatpanah CR; Peroutka SJ
Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
[TBL] [Abstract][Full Text] [Related]
9. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
Freezer A; Salem A; Irvine RJ
Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
[TBL] [Abstract][Full Text] [Related]
10. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
Hewitt KE; Green AR
Neuropharmacology; 1994 Dec; 33(12):1589-95. PubMed ID: 7539115
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1998 Oct; 19(4):265-77. PubMed ID: 9718590
[TBL] [Abstract][Full Text] [Related]
12. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').
Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
Neuropsychopharmacology; 2005 Mar; 30(3):550-60. PubMed ID: 15496938
[TBL] [Abstract][Full Text] [Related]
13. 5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis.
Matsumoto T; Maeno Y; Kato H; Seko-Nakamura Y; Monma-Ohtaki J; Ishiba A; Nagao M; Aoki Y
Eur Neuropsychopharmacol; 2014 Aug; 24(8):1362-70. PubMed ID: 24862256
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
15. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
Steele TD; Nichols DE; Yim GK
Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126
[TBL] [Abstract][Full Text] [Related]
16. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
Broening HW; Bowyer JF; Slikker W
J Pharmacol Exp Ther; 1995 Oct; 275(1):325-33. PubMed ID: 7562567
[TBL] [Abstract][Full Text] [Related]
18. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat.
O'Loinsigh ED; Boland G; Kelly JP; O'Boyle KM
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):621-38. PubMed ID: 11371001
[TBL] [Abstract][Full Text] [Related]
19. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine.
Hashimoto K; Maeda H; Goromaru T
Eur J Pharmacol; 1992 Sep; 228(2-3):171-4. PubMed ID: 1280228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
